iShares Self-Driving EV and Tech vs Neurocrine Biosciences Inc — how do they compare? iShares Self-Driving EV and Tech trades at $33.17 (market cap $264.50M), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 54.3× iShares Self-Driving EV and Tech's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 73 Days and Neurocrine Biosciences Inc for 23 Days on average.
| IDRV | NBIX | |
|---|---|---|
Market Cap | $264.50M | $14.36B |
Volume | 48,021 | 1,237,180 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $185.50 |
52-Week Low | $32.68 | $123.10 |
Typical Hold Time | 73 Days | 23 Days |
Enterprise Value | — | $14.37B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →